聚腺苷二磷酸-核糖聚合酶 (PARP) 抑制剂
一项随机Ⅱ期试验评估了 PARP 抑制剂依尼帕尼 (iniparib) 对转移性三阴乳腺癌患者的疗效。在这项试验中，随机分配到氟尿嘧啶、卡铂和依尼帕尼联合治疗组的患者的临床受益率、反应率、无进展生存期和总生存期显著优于氟尿嘧啶和卡铂联合治疗组。虽然存在这些积极结果，但一项验证性Ⅲ期试验未能看到总生存期和无进展生存期的统计学显著差异。[248]O'Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014;32:3840-3847.http://ascopubs.org/doi/full/10.1200/JCO.2014.55.2984http://www.ncbi.nlm.nih.gov/pubmed/25349301?tool=bestpractice.com[249]O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol. 2009;27:18s(suppl; abstr 3).http://meetinglibrary.asco.org/content/33185-65
卡铂
在标准新辅助化疗中加用卡铂已被发现可显著增加Ⅱ期至Ⅲ期三阴乳腺癌（即无雌激素、孕激素或 HER2 受体）患者的病理完全缓解 (pCR) 率。[250]Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13-21.http://ascopubs.org/doi/full/10.1200/JCO.2014.57.0572http://www.ncbi.nlm.nih.gov/pubmed/25092775?tool=bestpractice.com[251]Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14:933-942.http://www.ncbi.nlm.nih.gov/pubmed/23932548?tool=bestpractice.com
